Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in ...

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

Stéphane Bancel, chief executive of Cambridge-based Moderna, said in a statement that resolving the case “removes uncertainty." ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the ...

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable ...

Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the first single shot to ...

The recommendation from regulators paves the way for the shot’s approval in the European Union at a time the company is ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...